|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunosuppressant
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2007
|
|
gptkbp:ATCCode
|
L04AA25
|
|
gptkbp:brand
|
gptkb:Soliris
|
|
gptkbp:CASNumber
|
219685-50-4
|
|
gptkbp:cost
|
very high
|
|
gptkbp:developedBy
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:halfLife
|
270-375 hours
|
|
gptkbp:hasMolecularFormula
|
C6432H9952N1732O2010S52
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
eculizumab
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits terminal complement activation
|
|
gptkbp:origin
|
humanized monoclonal antibody
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:product
|
gptkb:IgG2/4_kappa
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
headache
hypertension
increased risk of meningococcal infection
|
|
gptkbp:target
|
gptkb:complement_protein_C5
|
|
gptkbp:UNII
|
8Q2K6F1K73
|
|
gptkbp:usedFor
|
gptkb:paroxysmal_nocturnal_hemoglobinuria
gptkb:atypical_hemolytic_uremic_syndrome
gptkb:neuromyelitis_optica_spectrum_disorder
generalized myasthenia gravis
|
|
gptkbp:bfsParent
|
gptkb:PNH
|
|
gptkbp:bfsLayer
|
6
|